ENDRA Life Sciences reports Q4 net loss $3.3M, cash $4.9M; advances TAEUS regulatory submission

ENDRA Life Sciences Inc.

Net loss Q4 2022 $3.3M ($1.04/share) vs Q4 2021 $3.1M ($1.48/share); FY2022 net loss $13.2M ($4.56/share).
Cash and equivalents $4.9M at Dec 31, 2022; company notes exposure to SVB failure but deposits spread across multiple banks.
Over 100 TAEUS scans at clinical sites in 2022; interactive guidance tool deployed to improve operator performance.
Plans to submit De Novo request to FDA for TAEUS liver device; renewed GE HealthCare collaboration through Dec 2024.
Operating expenses up to $3.3M in Q4 and $13.2M in FY, driven by product development and European commercialization.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ENDRA Life Sciences Inc. reported the fourth quarter of 2022 results: net income Net loss in the fourth quarter of 2022 was $3.3 million, or $1.04 per share, EPS $1.04 per share.

Period: the fourth quarter of 2022
Net income: Net loss in the fourth quarter of 2022 was $3.3 million, or $1.04 per share
EPS: $1.04 per share
Result: reported results

Exact text from the filing

Net loss in the fourth quarter of 2022 was $3.3 million, or $1.04 per share, compared with a net loss of $3.1 million, or $1.48 per share, in the fourth quarter of 2021.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ENDRA Life Sciences Inc. reported the year ended December 31, 2022 results: net income Net loss in 2022 was $13.2 million, or $4.56 per share, EPS $4.56 per share.

Period: the year ended December 31, 2022
Net income: Net loss in 2022 was $13.2 million, or $4.56 per share
EPS: $4.56 per share
Result: reported results

Exact text from the filing

Net loss in 2022 was $13.2 million, or $4.56 per share, compared with a net loss of $11.2 million, or $5.55 per share, in 2021.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

ENDRA Life Sciences Inc. filing history →

Source: SEC EDGAR

accession 0001654954-23-002841

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.